Abstract:Objectives: To determine if baseline characteristics, treatment efficacy, psychosocial outcomes or tolerability were associated with patient preference for sildenafil citrate (sildenafil) or tadalafil for treating erectile dysfunction (ED) in men naive to phosphodiesterase 5 inhibitor therapy. Patients and methods: In an open-label, crossover study of sildenafil (25, 50 or 100 mg) and tadalafil (10 or 20 mg), dosed as needed, after a 4-week baseline assessment, 367 men with ED were randomly assigned to sildenafil followed by tadalafil or vice versa (8-week dose optimization and 4-week assessment phase for each treatment period). Patients completing both periods chose which treatment they preferred for an 8-week extension phase. Bivariate logistic regression and stepwise logistic regression were used to determine if any baseline characteristics or post-baseline measurements were associated with the patients' treatment preference. Baseline variables examined were age, race, ED aetiology/duration, body mass index, smoking status, alcohol consumption, vital signs, comorbid medical conditions, and baseline scores for the International Index of Erectile Function (IIEF) domains, Psychological and Interpersonal Relationship Scales (PAIRS) domains, and Sexual Encounter Profile (SEP) diary questions. Post-baseline variables examined were therapy sequence, dosage, and differences in IIEF and PAIRS domains, SEP scores, in number/timing of sexual attempts and in the severity of side-effects (overall patient perception). Results: Of 291 patients completing both treatments and indicating a preference, 85 (29%) preferred sildenafil and 206 (71%) preferred tadalafil. Variables were individually analysed using bivariate analysis; one baseline characteristic (presence/absence of hyperlipidaemia) and 13 post-baseline measurements were significantly associated with the patients' treatment preference. Variables were analysed as a group using stepwise logistic regression; a set of six post-baseline factors was identified as significantly associated with patient preference. Dosage choice, reductions in the PAIRS time concerns domain, IIEF intercourse satisfaction domain improvements, smaller side-effect severity scores, more sexual attempts, and increased SEP4 scores (satisfaction with erection hardness) during the tadalafil or sildenafil treatment periods were all significantly associated with preference for tadalafil or sildenafil. Conclusions: We identified no baseline characteristics that prospectively distinguish patients who will prefer tadalafil or sildenafil. Patient differences in time concerns, dosage choice, intercourse satisfaction, treatment tolerability, number of sexual attempts and satisfaction with erection hardness were the set of factors most significantly associated with treatment preference, and the preference observed for tadalafil (71%) or sildenafil (29%) might be substantially accounted for by differences in these factors during the tadalafil and sildenafil treatment periods.

Causes of tadalafil failure and rechallenging treatment

Causes of on-demand sildenafil failure and rechallenging treatment

Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction

Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses

A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy

Letter to Editor on "Unresolved questions in the recovery of spontaneous erectile function in young men treated with daily tadalafil"

An Open-Label, Multicenter, Randomized, Crossover Study Comparing Sildenafil Citrate and Tadalafil for Treating Erectile Dysfunction in Chinese Men Naïve to Phosphodiesterase 5 Inhibitor Therapy.

Long-term tadalafil once daily in Chinese men with erectile dysfunction: a 2-year final analysis of a post-marketing, multicenter, randomized, open-label trial

Benefits of Tadalafil to ED Patients

Evaluation of the long-term safety and effectiveness of tadalafil once daily in Chinese men with erectile dysfunction: interim results of a multicenter, randomized, open-label trial

Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies

A Randomized Clinical Trial Investigating Treatment Choice in Chinese Men Receiving Sildenafil Citrate and Tadalafil for Treating Erectile Dysfunction

Efficacy and Safety of On‐demand Tadalafil for the Treatment of Erectile Dysfunction in South‐East Asian Men

Spontaneous erectile function recovery among young men with erectile dysfunction taking tadalafil 5 mg once a day

Efficacy and Safety of Tadalafil Taken As Needed for the Treatment of Erectile Dysfunction in Asian Men: Results of an Integrated Analysis.

Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study

[Low-Dose Tadalafil Combined with Shuganyiyang Capsules for Mild-to-moderate Erectile Dysfunction].

Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction

Short- and long-term follow-up results of daily 5-mg tadalafil as a treatment for erectile dysfunction and premature ejaculation

Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study

[Efficacy of Tadalafil for Erectile Dysfunction: an Updated Review].